Current issues of severe herpetic infection in adults

Galavit tablets: composition

The activity of the drug against viral infections is explained by the presence of sodium aminodihydrophthalazinedione in the active substance. The patented name of this component is Galavit. The auxiliary components are:

• starch;
• lactose;
• sorbitol;
• menthol;
• calcium stearate.

The drug is an immunomodulator that has an anti-inflammatory effect. You can find the drug in the pharmacy not only in the form of tablets, but also in the form of rectal suppositories.

References

1. Sologub T.V., Osinovets O.Yu. Use of the immunomodulatory drug Galavit in the complex therapy of influenza // Clinician. 2012. No. 2.
2. Ermishina V.I., Kazeko N.I., Oskolkov S.A. Results of using the immunomodulatory drug “Galavit” for complicated chronic pyelonephritis and urolithiasis // Tyumen Medical Journal. 2015. No. 3.
3. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharm Des. 2009;15(11):1238-47. doi: 10.2174/138161209787846847. PMID: 19355963.
4. da Silva EG, Gionfriddo JR, Hudachek SF, Gustafson DL, Olea-Popelka FJ, Scofield VL, Powell CC, Hill AE. Evaluation of the ocular penetration of topical alpha-luminol (Galavit®/GVT®). Vet Ophthalmol. 2011 May;14(3):180-5. doi: 10.1111/j.1463-5224.2010.00862.x. PMID: 21521442.

What is the medicine Galavit for?

Activity against viruses is explained by the regulatory effect on the work of innate and acquired immune cells, including macrophages, neutrophils and killer cells. As a result, the body equips itself with its own means against fungi, viruses and bacteria. The pathogens die quickly without having time to develop pronounced symptoms of the disease.

In addition, Galavit processes the formation of antibodies and their activity, and also triggers the natural production of its own interferon, which mobilizes the cells of the mucous membranes against infection by viruses, which does not allow microorganisms to produce similar individuals. As a result, each unit of the virus, without having time to produce offspring, will complete its life cycle and die.

The drug can be used by children over 12 years of age and adults, including those with identified secondary immune deficiency. Indications for use are:

• bronchitis;
• pneumonia;
• otitis;
• tonsillitis;
• adenitis;
• flu;
• periodontal disease;
• stomatitis;
• laryngitis.

Also, during recurrent episodes of the herpes virus, Galavit restores the body’s natural protective function, helping to contain the pathogen in a state of suspended animation.

If a general loss of strength is caused by abandonment of the body, Galavit helps to restore strength and gain a high level of performance: not only mental, but also physical.

Nosological classification (ICD-10)

• A04.9 Bacterial intestinal infection, unspecified
• A09 Diarrhea and gastroenteritis of presumably infectious origin (dysentery, bacterial diarrhea)
• A41.8 Other specified septicemia
• A46 Erysipelas
• A48.3 Toxic shock syndrome
• A56.0 Chlamydial infections of the lower genitourinary tract
• A56.2 Chlamydial infection of the genitourinary tract, unspecified
• A59.0 Urogenital trichomoniasis
• B00 Infections caused by herpes simplex virus
• B19 Viral hepatitis, unspecified
• B34 Viral infection of unspecified localization
• B97.7 Papillomaviruses
• D26 Other benign neoplasms of the uterus
• D84.9 Immunodeficiency, unspecified
• E63 Physical and mental overload
• F06.6 Organic emotionally labile [asthenic] disorder
• F10 Mental and behavioral disorders caused by alcohol use
• F10.3 Withdrawal state
• F11 Mental and behavioral disorders caused by opioid use
• F12 Mental and behavioral disorders caused by cannabinoid use
• F45 Somatoform disorders
• F48 Other neurotic disorders
• F48.0 Neurasthenia
• G90 Disorders of the autonomic nervous system
• H66.9 Otitis media, unspecified
• J02 Acute pharyngitis
• J02.9 Acute pharyngitis, unspecified
• J06 Acute upper respiratory tract infections of multiple and unspecified localization
• J18 Pneumonia without specifying the pathogen
• J31.2 Chronic pharyngitis
• J35.0 Chronic tonsillitis
• J35.2 Adenoid hypertrophy
• J35.9 Chronic disease of tonsils and adenoids, unspecified
• J39.9 Upper respiratory tract disease, unspecified
• J40 Bronchitis, not specified as acute or chronic
• J86 Pyothorax
• J98.8 Other specified respiratory disorders
• K05.6 Periodontal disease, unspecified
• K12 Stomatitis and related lesions
• K13.7 Other and unspecified lesions of the oral mucosa
• K25 Stomach ulcer
• K26 Duodenal ulcer
• K35 Acute appendicitis
• K65 Peritonitis
• L02 Skin abscess, boil and carbuncle
• M86.6 Other chronic osteomyelitis
• N34 Urethritis and urethral syndrome
• N39.0 Urinary tract infection without established location
• N41.0 Acute prostatitis
• N41.1 Chronic prostatitis
• N49 Inflammatory diseases of the male genital organs, not elsewhere classified
• N70 Salpingitis and oophoritis
• N70.0 Acute salpingitis and oophoritis
• N70.1 Chronic salpingitis and oophoritis
• N71 Inflammatory diseases of the uterus, except the cervix
• N73.9 Inflammatory diseases of the female pelvic organs, unspecified
• R53 Malaise and fatigue
• T30 Thermal and chemical burns of unspecified location
• T79.3 Post-traumatic wound infection, not elsewhere classified
• Z100* CLASS XXII Surgical practice
• Z40 Preventive surgery
• Z50.2 Rehabilitation for alcoholism
• Z50.3 Drug rehabilitation
• Z51.0 Radiotherapy course
• Z51.1 Chemotherapy for neoplasm
• Z54.0 Convalescent period after surgery
• Z73.6 Restrictions in activity caused by decreased ability to work
• Z98.8 Other specified postsurgical conditions

Galavit tablets: instructions

Take Galavit tablets up to 4 times a day. The tablets are not intended to be swallowed, as gastric juice and duodenal acid reduce the effectiveness of the drug by reacting chemically with its active component. Therefore, to achieve maximum effect, the tablet is placed under the tongue. Dissolving in saliva, the active substance is quickly absorbed into the blood through many capillaries of the sublingual space.

Dosage:

• 1 tablet every 4 hours, maximum daily dose – 4 tablets per day.
• 2 tablets every 12 hours.

For diseases of the lower respiratory tract (bronchitis and pneumonia), take 1 tablet 4 times a day for 5 days. If the disease is chronic, prescribe 1 tablet 4 times a day, every other day, for two weeks.

During epidemics of seasonal diseases, as a preventive measure for infection, take 1 tablet twice a day for 7 days. To get rid of inflammation of the oral cavity, such as periodontal disease or stomatitis, take 1 tablet 4 times a day for 5 days in a row. And after 5 days, 1 tablet 4 times a day with an interval of 3 days for 20 days.

To restore immunity in case of chronic lesions of the herpes virus, dissolve 1 tablet every 4-5 hours for 10 days in a row. Then take 1 tablet 4 times every other day for the next 10 days.

In order to restore performance and physical activity, prescribe 1 dose 4 times a day for 10 days, and after 10 days, take 1 tablet every 4 hours with an interval of 3 days for 3 weeks.

Treatment can be started at any stage of infection. If after the specified period there is no improvement, or new symptoms begin to appear, you need to contact a specialist for an in-person consultation.

What else is prescribed with this study?

Immune status (screening) (Phagocytic activity of leukocytes, cellular immunity, total immunoglobulin IgE, immunoglobulins IgA, IgM, IgG)

27.960. Ven. blood 3 days

7,700 ₽ Add to cart

Immune status expanded

17.61. Ven. blood 14 days

22,500 ₽ Add to cart

Cellular immunity (T-lymphocytes, T-helpers, T-cytotoxic cells, Immunoregulatory index, B-lymphocytes, NK-T cells, NK cells, Leukocyte formula)

17.50. Ven. blood 3 days

5 210 ₽ Add to cart

Contraindications

Direct contraindications to the use of Galavit are:

• galactose intolerance;
• lactase deficiency;
• pregnancy;
• lactation period;
• the patient's age is less than 12 years.

Galavit does not affect the nervous system, does not inhibit reactions, does not interfere with driving, and does not reduce the ability to make important decisions in a short time.

Clinical studies of Galavit for COVID-19

For 2022, 2 small clinical studies of Galavit for coronavirus infections are known (if you know more, please tell us in the comments):

1. Prevention of moderate and severe forms of COVID-19 with Galavit among medical personnel in the “red zone” (June 2020): symptoms of coronavirus infection occurred in 6.4%
   of medical workers in the “red zone” who took Galavit, and in
   17.6%
   of those who did not, the difference was statistically reliable;
2. (PDF) Use of Galavit to prevent the progression of pneumonia in COVID-19 (Therapeutic archive 11, 2020): 22 patients with
   moderate to severe COVID pneumonia with an average age of 62 years and lung damage according to CT from 25 to 75% in the second week from At the onset of the disease, Galavit was added to the treatment. In all patients, shortness of breath and acrocyanosis quickly decreased, and there were positive changes in CT and laboratory parameters. No one needed a ventilator, and no one died.

Unfortunately, these studies are small, therefore, from a Western point of view, Galavit should be classified as drugs with unproven effectiveness. However, doctors who have worked with this drug have good reviews of it. For influenza, Galavit lowered the temperature and accelerated recovery, also eliminating asthenic syndrome (a feeling of weakness after an infection).

Side effects from taking Galavit

Rarely, when taking Galavit, allergic reactions occur in the form of a rash on the skin or irritation of the mucous membranes at the site of contact with the drug. At the first signs of such allergic reactions, you should stop taking it and consult a doctor.

Negative reactions of the body in response to the use of Galavit that are not described in the instructions are possible. If, after starting treatment, your general condition worsens, nausea appears, headaches or abdominal pain begin, stop the drug and consult a specialist to prescribe a different course of treatment.

Release form

Powder for preparing a solution for intramuscular administration. In a bottle, 50 mg, 100 mg. 3 or 5 fl. in a cardboard box.

Rectal suppositories, 50 mg, 100 mg. In blister pack, 5 pcs. 1 or 2 contour packages in a cardboard box.

Sublingual tablets, 25 mg. In blister packs made of PVC film and aluminum foil, 10 or 20 pcs. 1, 2, 3 or 4 contour packages in a cardboard box. 10, 20, 30, 40 or 50 contour packs in group packaging.

Security assessment

When analyzing information on the safety of a drug containing sodium aminodihydrophthalazindione, the following information was found. In 2001, a working group of the Swiss League Against Cancer assessed a drug containing aminodihydrophthalazindione sodium for use in oncology and stated that there was no basis for its use, and also drew attention to the “similarity of the active substance of the drug with luminol, which has an allergenic potential and, according to Swiss legislation must be disposed of as a toxic substance" [16]. In the instructions for the drug containing sodium aminodihydrophthalazindione, in the section “Possible side effects when using the drug” it is stated: “in rare cases, allergic reactions are possible” [1]. No publications on toxicological studies of sodium aminodihydrophthalazinedione could be found. Publications were found on toxicological studies of luminol, which is similar in chemical structure to sodium aminodihydrophthalazinedione. The oral LD50 dose of luminol in rats is >500 mg/kg [17]. The following adverse reactions have been observed in animal models: increased diuresis and natriuresis and decreased blood pressure in dogs following a single intravenous dose of 2.5 mg [17]. At doses of 250–1000 μM, luminol significantly increases the frequency of crossing over (during S-phase and in the presence of bromodeoxyuridine) in Chinese hamster V79 cell culture in vitro [17], which may indicate the potential mutagenicity and carcinogenicity of luminol in studies in an animal model.